Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05319028 · ClinicalTrials.gov registry record · Phase 2
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by Calithera Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05319028: Clinical Trial Phase 2 study, sponsored by Calithera Biosciences.
NCT05319028 is a Phase 2 study that was terminated before completion, run by Calithera Biosciences. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05319028, a Phase 2 study, was terminated before completion, sponsored by Calithera Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL, incorporating ctDNA-based next-generation sequencing (NGS) to identify DLBCL patients harboring MyD88 and/or CD79B mutations within the study. This goal of this strategy is to evaluate its activity both in the cell-of-origin subgroup of non-GCB/ABC DLBCL and in the genetically defined subgroups of MyD88/CD79B-mutated and wild type DLBCL.
Primary Outcome
Overall response is defined as a complete response (CR) or partial response (PR). ORR is the proportion of participants who have overall responses.
Interventions
- DRUG Mivavotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2023-02-24 |
| Phase | Phase 2 |
Why NCT05319028 stopped before completion
NCT05319028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Mivavotinib is the first listed.
NCT05319028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05319028 about?
NCT05319028 is a clinical study titled "Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL, incorporating ctDNA-based next-generation sequencing (NGS) to identify DLBCL patients harboring MyD88 and/or CD79B ...
What is the current status of trial NCT05319028?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-06-23. Estimated completion is 2023-02-24.
What interventions are being tested in trial NCT05319028?
The interventions under investigation include: Mivavotinib (DRUG).
Who is sponsoring clinical trial NCT05319028?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05319028's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI